{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-299165","form_type":"8-K","ticker":"VERA","cik":"0001831828","company_name":"Vera Therapeutics, Inc.","filed_at":"2026-07-09T12:00:16+00:00","discovered_at":"2026-07-09T12:05:00.822326+00:00","generated_at":"2026-07-09T12:05:10.609456+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Vera Therapeutics announces CRO transition: Turner to Special Advisor, Bowman appointed Chief Regulatory Officer","bullets":["William Turner steps down as Chief Regulatory Officer, becomes Special Advisor for Regulatory Affairs effective August 3, 2026.","Nancy Bowman, M.D., Ph.D., appointed as new Chief Regulatory Officer, effective August 3, 2026.","Transition appears planned; no reason for departure given."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-299165","json":"https://secwatch.observer/filing/0001193125-26-299165.json","markdown":"https://secwatch.observer/filing/0001193125-26-299165.md","text":"https://secwatch.observer/filing/0001193125-26-299165.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831828/000119312526299165/0001193125-26-299165-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831828/000119312526299165/vera-20260709.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-09T12:05:10.609456+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}